# U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer

- Source: PR Newswire M&A
- Published: 2026-11-06T14:57:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/us-fda-approves-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-co-formulated-with-halozymes-enhanze-technology-for-the-treatment-of-advanced-head-and-neck-cancer-302932125.html
- Canonical: https://groundlevelnews.com/story/u-s-fda-approves-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-c-649cfa/

Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & Johnson was granted accelerated approval from the U.S. Food and Drug...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._